journal article·2026-07-13Open access

HMGCR‐Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence

Xiaoqi Zhang, Siru Zhou, Xi Liu, Wei Xiang, Xiuqin Peng, Yu Tian, Song Li, Hailin Wang, Bo Liao, Shunzheng Fang, Runze Jin, Jinhui Wu, Chuanqing Bai, Wei Zhang, Bo Huang, Bingfei Li, Lifeng Chen, Lin Chen, Bin Zhang, Zhenhong Ni

Abstract

ABSTRACT Dysregulated cholesterol metabolism has been implicated in several aging‐associated disorders, including osteoarthritis (OA). 3‐Hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) is the key enzyme in cholesterol biosynthesis, but the role of HMGCR in OA and the underlying mechanism remain unclear. In this study, we found that HMGCR + fibroblasts (FLSs) were significantly increased in the knee synovium of OA patients and OA mice. Elevated expression of HMGCR in synovial FLSs was positively correlated with cellular senescence and OA progression. The inhibition of HMGCR reversed cellular senescence of FLSs induced by TNF‐α in vitro. Additionally, the HMGCR‐mediated cholesterol biosynthetic pathway contributed to cellular senescence. Targeted inhibition of HMGCR in synovial FLSs via intra‐articular adeno‐associated virus delivery effectively reversed cellular senescence of FLSs and mitigated synovitis, cartilage degradation, and pain behaviors in OA mice. Mechanistically, the phosphorylation of AKT1 at Ser473 enhanced its binding to Lys140 of Insig1, facilitating AKT1–Insig1 complex formation. The activation of AKT1 induced the phosphorylation of Insig1 at Ser189 and the dissociation of Insig1 from sterol regulatory element‑binding protein cleavage‑activating protein (SCAP), which contributed to HMGCR transcription and cellular senescence of FLSs. Collectively, our study reveals a novel mechanism of HMGCR‐driven cellular senescence of FLSs in OA, which highlights HMGCR as a promising therapeutic target for OA.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Cholesterol and Lipid Metabolism · Lipoproteins and Cardiovascular Health

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Rehabilitation Medicine Army Medical Center Daping Hospital Army Medical University of PLA Chongqing China

War Trauma Medical Center State Key Laboratory of Trauma and Chemical Poisoning Army Medical Center Daping Hospital Army Medical University Chongqing China

Department of Otorhinolaryngology and Maxillofacial Surgery The 988th Hospital of the Joint Logistics Support Force Zhengzhou China

Metabolism and Repair Laboratory For Prevention and Rehabilitation of Training Injuries State Key Laboratory of Trauma and Chemical Poisoning Trauma Center Research Institute of Surgery Army Medical Center Daping Hospital Army Medical University of PLA Chongqing China

Department of Rehabilitation Medicine Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission The First Affiliated Hospital of Chongqing Medical University Chongqing China

Department of Emergency Medicine Army Medical Center Daping Hospital Army Medical University of PLA Chongqing China

Rehabilitation Center Key Specialty of Neck and Low Back Pain Rehabilitation Xingcheng Special Duty Sanatorium Xingcheng China

Funding

National Natural Science Foundation of China

References (68)

Show source-provided references
1. 10.1038/s41572‐025‐00594‐610.1038/s41572‐025‐00594‐6 ↗
2. 10.1016/S2665‐9913(23)00163‐710.1016/S2665‐9913(23)00163‐7 ↗
3. 10.1038/s41584‐022‐00749‐910.1038/s41584‐022‐00749‐9 ↗
4. 10.3390/jcm1204133110.3390/jcm12041331 ↗
5. 10.3390/ijms25221208210.3390/ijms252212082 ↗
6. 10.1016/j.joca.2010.07.00810.1016/j.joca.2010.07.008 ↗
7. 10.1080/15548627.2019.166470510.1080/15548627.2019.1664705 ↗
8. 10.1038/s41580‐019‐0190‐710.1038/s41580‐019‐0190‐7 ↗
9. 10.1038/nri379310.1038/nri3793 ↗
10. 10.1038/s42255‐020‐0174‐010.1038/s42255‐020‐0174‐0 ↗
11. 10.1016/j.cmet.2021.09.00110.1016/j.cmet.2021.09.001 ↗
12. 10.1038/s41586‐019‐0920‐110.1038/s41586‐019‐0920‐1 ↗
13. 10.1002/art.4298410.1002/art.42984 ↗
14. 10.1038/343425a010.1038/343425a0 ↗
15. 10.1016/j.semcancer.2020.07.01410.1016/j.semcancer.2020.07.014 ↗
16. 10.1371/journal.pgen.100828910.1371/journal.pgen.1008289 ↗
17. 10.1016/j.molmet.2021.10124410.1016/j.molmet.2021.101244 ↗
18. 10.1371/journal.pone.003575310.1371/journal.pone.0035753 ↗
19. 10.1038/s43587‐025‐00907‐010.1038/s43587‐025‐00907‐0 ↗
20. 10.1136/ard‐2022‐22277310.1136/ard‐2022‐222773 ↗
21. 10.1038/s41591‐022‐01923‐y10.1038/s41591‐022‐01923‐y ↗
22. 10.1038/s41413‐024‐00375‐z10.1038/s41413‐024‐00375‐z ↗
23. 10.1136/annrheumdis‐2021‐22109110.1136/annrheumdis‐2021‐221091 ↗
24. 10.1038/s41467‐024‐55335‐210.1038/s41467‐024‐55335‐2 ↗
25. 10.1016/j.arr.2024.10229410.1016/j.arr.2024.102294 ↗
26. 10.1038/s42255‐023‐00747‐510.1038/s42255‐023‐00747‐5 ↗
27. 10.1038/s41514‐023‐00128‐y10.1038/s41514‐023‐00128‐y ↗
28. 10.1038/s41467‐025‐56002‐w10.1038/s41467‐025‐56002‐w ↗
29. 10.1038/s41590‐022‐01376‐y10.1038/s41590‐022‐01376‐y ↗
30. 10.1016/j.celrep.2024.11410210.1016/j.celrep.2024.114102 ↗
31. 10.1038/s41467‐022‐34801‐910.1038/s41467‐022‐34801‐9 ↗
32. 10.1038/s41580-020-00314-w10.1038/s41580-020-00314-w ↗
33. 10.1038/s41467‐022‐32158‐710.1038/s41467‐022‐32158‐7 ↗
34. 10.1038/s41413‐021‐00164‐y10.1038/s41413‐021‐00164‐y ↗
35. 10.1002/advs.20241452510.1002/advs.202414525 ↗
36. 10.1038/s41392‐022‐01125‐510.1038/s41392‐022‐01125‐5 ↗
37. 10.1038/s41586‐020‐2183‐210.1038/s41586‐020‐2183‐2 ↗
38. 10.1016/j.cell.2017.04.00110.1016/j.cell.2017.04.001 ↗
39. 10.1038/s41422‐018‐0123‐610.1038/s41422‐018‐0123‐6 ↗
40. 10.1038/sj.emboj.760004510.1038/sj.emboj.7600045 ↗
41. 10.1126/science.105949710.1126/science.1059497 ↗
42. 10.1038/emboj.2009.23910.1038/emboj.2009.239 ↗
43. 10.1016/j.ccr.2008.11.00310.1016/j.ccr.2008.11.003 ↗
44. 10.1016/j.joca.2020.02.02710.1016/j.joca.2020.02.027 ↗
45. 10.1038/s41419‐024‐06427‐w10.1038/s41419‐024‐06427‐w ↗
46. 10.1038/s41401‐018‐0079‐610.1038/s41401‐018‐0079‐6 ↗
47. 10.1016/j.jhep.2014.12.00610.1016/j.jhep.2014.12.006 ↗
48. 10.1016/j.bbamcr.2011.09.01710.1016/j.bbamcr.2011.09.017 ↗
49. 10.1016/j.lfs.2018.04.02810.1016/j.lfs.2018.04.028 ↗
50. 10.1002/art.3933710.1002/art.39337 ↗
51. 10.1016/j.atherosclerosis.2022.05.01510.1016/j.atherosclerosis.2022.05.015 ↗
52. Cholesterol Accumulation Caused by Low Density Lipoprotein Receptor Deficiency or a Cholesterol‐Rich Diet Results in Ectopic Bone Formation during Experimental Osteoarthritis10.1186/ar4367 ↗
53. 10.1038/s41467‐025‐65689‐w10.1038/s41467‐025‐65689‐w ↗
54. 10.1016/j.joca.2021.02.57010.1016/j.joca.2021.02.570 ↗
55. IL‐1β Inhibition Combined with Cholesterol‐Lowering Therapies Decreases Synovial Lining Thickness and Spontaneous Cartilage Degeneration in a Humanized Dyslipidemia Mouse Model10.1016/j.joca.2022.09.014 ↗
56. Intensive Cholesterol‐Lowering Treatment Reduces Synovial Inflammation during Early Collagenase‐Induced Osteoarthritis, but Not Pathology at End‐Stage Disease in Female Dyslipidemic E3L.CETP Mice10.1016/j.joca.2023.01.577 ↗
57. 10.1186/s13045‐022‐01381‐610.1186/s13045‐022‐01381‐6 ↗
58. 10.1002/ctm2.7020210.1002/ctm2.70202 ↗
59. 10.1186/s13046‐017‐0490‐810.1186/s13046‐017‐0490‐8 ↗
60. 10.1080/15548627.2024.239579710.1080/15548627.2024.2395797 ↗
61. 10.1002/art.4237810.1002/art.42378 ↗
62. 10.3390/antiox1207143210.3390/antiox12071432 ↗
63. 10.1038/s41467‐023‐41858‐710.1038/s41467‐023‐41858‐7 ↗
64. 10.1136/annrheumdis‐2019‐21569610.1136/annrheumdis‐2019‐215696 ↗
65. 10.1002/advs.20230718510.1002/advs.202307185 ↗
66. 10.1016/j.joca.2025.05.00410.1016/j.joca.2025.05.004 ↗
67. 10.1016/j.bbalip.2017.03.00910.1016/j.bbalip.2017.03.009 ↗
68. 10.1093/nar/gkac94710.1093/nar/gkac947 ↗